JP2011500838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500838A5 JP2011500838A5 JP2010531258A JP2010531258A JP2011500838A5 JP 2011500838 A5 JP2011500838 A5 JP 2011500838A5 JP 2010531258 A JP2010531258 A JP 2010531258A JP 2010531258 A JP2010531258 A JP 2010531258A JP 2011500838 A5 JP2011500838 A5 JP 2011500838A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- ppm
- subclass
- penicillin
- specifically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 43
- 239000012530 fluid Substances 0.000 claims description 42
- 150000002960 penicillins Chemical class 0.000 claims description 19
- -1 pibmesilinum Chemical compound 0.000 claims description 19
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 12
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000004068 intracellular signaling Effects 0.000 claims description 9
- 210000004379 membrane Anatomy 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 210000002390 cell membrane structure Anatomy 0.000 claims description 7
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 7
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 7
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 5
- 229960002292 piperacillin Drugs 0.000 claims description 5
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 229960003669 carbenicillin Drugs 0.000 claims description 4
- 229960003326 cloxacillin Drugs 0.000 claims description 4
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 229960004273 floxacillin Drugs 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 229960001019 oxacillin Drugs 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 229940056360 penicillin g Drugs 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229960004659 ticarcillin Drugs 0.000 claims description 4
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- 230000008728 vascular permeability Effects 0.000 claims description 4
- 230000024883 vasodilation Effects 0.000 claims description 4
- 229930195708 Penicillin V Natural products 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 229960001585 dicloxacillin Drugs 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229960000515 nafcillin Drugs 0.000 claims description 3
- 229940056367 penicillin v Drugs 0.000 claims description 3
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 3
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- 229940090588 amoxil Drugs 0.000 claims description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Polymers [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 2
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 claims description 2
- 229960002699 bacampicillin Drugs 0.000 claims description 2
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 claims description 2
- JAQPGQYDZJZOIN-LQDWTQKMSA-N benzylpenicillin benethamine Chemical compound C=1C=CC=CC=1C[NH2+]CCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 JAQPGQYDZJZOIN-LQDWTQKMSA-N 0.000 claims description 2
- 229940118531 bicillin Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000001047 desmosome Anatomy 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 claims description 2
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 229940052726 permapen Drugs 0.000 claims description 2
- 229940066843 pfizerpen Drugs 0.000 claims description 2
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 claims description 2
- 229960003342 pivampicillin Drugs 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 229940055815 trimox Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 2
- 101710095468 Cyclase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000009134 cell regulation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004692 intercellular junction Anatomy 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- PPKPKFIWDXDAGC-IHWYPQMZSA-N (z)-1,2-dichloroprop-1-ene Chemical compound C\C(Cl)=C\Cl PPKPKFIWDXDAGC-IHWYPQMZSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98271907P | 2007-10-25 | 2007-10-25 | |
| US98272007P | 2007-10-25 | 2007-10-25 | |
| PCT/US2007/082581 WO2008115290A2 (en) | 2006-10-25 | 2007-10-25 | Methods of wound care and treatment |
| USPCT/US2007/082580 | 2007-10-25 | ||
| USPCT/US2007/082578 | 2007-10-25 | ||
| USPCT/US2007/082581 | 2007-10-25 | ||
| US60/982,720 | 2007-10-25 | ||
| PCT/US2007/082578 WO2008052143A2 (en) | 2006-10-25 | 2007-10-25 | Mixing device and output fluids of same |
| US60/982,719 | 2007-10-25 | ||
| PCT/US2007/082580 WO2008052145A2 (en) | 2006-10-25 | 2007-10-25 | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US4840408P | 2008-04-28 | 2008-04-28 | |
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834008P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US4841608P | 2008-04-28 | 2008-04-28 | |
| US61/048,404 | 2008-04-28 | ||
| US61/048,416 | 2008-04-28 | ||
| US61/048,347 | 2008-04-28 | ||
| US61/048,340 | 2008-04-28 | ||
| US61/048,332 | 2008-04-28 | ||
| PCT/US2008/081029 WO2009055620A1 (en) | 2007-10-25 | 2008-10-23 | Bacteriostatic or bacteriocidal compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500838A JP2011500838A (ja) | 2011-01-06 |
| JP2011500838A5 true JP2011500838A5 (https=) | 2012-12-06 |
| JP5586470B2 JP5586470B2 (ja) | 2014-09-10 |
Family
ID=42238385
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531258A Expired - Fee Related JP5586470B2 (ja) | 2007-10-25 | 2008-10-23 | 静菌性または殺菌性組成物および方法 |
| JP2010531321A Expired - Fee Related JP5647897B2 (ja) | 2007-10-25 | 2008-10-27 | 喘息および他の肺障害を治療するための組成物および方法 |
| JP2014228037A Expired - Fee Related JP5750540B2 (ja) | 2007-10-25 | 2014-11-10 | 喘息および他の肺障害を治療するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531321A Expired - Fee Related JP5647897B2 (ja) | 2007-10-25 | 2008-10-27 | 喘息および他の肺障害を治療するための組成物および方法 |
| JP2014228037A Expired - Fee Related JP5750540B2 (ja) | 2007-10-25 | 2014-11-10 | 喘息および他の肺障害を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2207669A4 (https=) |
| JP (3) | JP5586470B2 (https=) |
| CN (3) | CN101909869B (https=) |
| AU (2) | AU2008316708A1 (https=) |
| CA (2) | CA2703648A1 (https=) |
| IL (2) | IL205321A0 (https=) |
| MX (1) | MX2010004549A (https=) |
| WO (1) | WO2009055620A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| BR112012028540A2 (pt) | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| JP6111194B2 (ja) | 2010-08-05 | 2017-04-05 | フォーサイト・ビジョン フォー・インコーポレーテッド | 組み合わせ薬物送達方法および装置 |
| SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP4249059B1 (en) | 2011-06-28 | 2025-07-30 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
| RS61758B1 (sr) | 2011-09-16 | 2021-05-31 | Forsight Vision4 Inc | Aparati za razmenu tečnosti |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| JP6159584B2 (ja) * | 2012-06-14 | 2017-07-05 | 松本 高明 | 輸液、輸液の製造方法および輸液装置 |
| CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| ES2972168T3 (es) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Implante oftálmico para administración de sustancias terapéuticas |
| GB201402513D0 (en) * | 2014-02-13 | 2014-04-02 | Cardiff Scintigraphics Ltd | Pressurised metered dose inhalers and method of manufacture |
| KR101930573B1 (ko) * | 2014-04-23 | 2018-12-18 | 주식회사 티씨엠생명과학 | 세포 도말 장치 및 세포 도말 방법 |
| EP3169289B1 (en) | 2014-07-15 | 2020-04-15 | ForSight Vision4, Inc. | Ocular implant delivery device |
| BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
| WO2016077371A1 (en) | 2014-11-10 | 2016-05-19 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
| CA3005238A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| JP7009384B2 (ja) | 2016-04-05 | 2022-01-25 | フォーサイト・ビジョン フォー・インコーポレーテッド | 移植可能な眼薬送達デバイス |
| JP7287888B2 (ja) * | 2016-06-27 | 2023-06-06 | ギャラリー，インコーポレイテッド | ジェネレータ、電極付きのカテーテル、及び肺通路の治療方法 |
| KR20200093581A (ko) | 2017-11-21 | 2020-08-05 | 포사이트 비젼4, 인크. | 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법 |
| US11759677B2 (en) | 2018-02-16 | 2023-09-19 | University Of Louisville Research Foundation, Inc. | Respiratory training and airway pressure monitoring device |
| KR102171489B1 (ko) * | 2018-10-30 | 2020-10-29 | (주)메가메디칼 | 네블라이저 및 산소공급기가 구비되는 네블라이저 장치 |
| EP4125847A4 (en) * | 2020-04-03 | 2024-06-19 | Lpoxy Therapeutics, Inc. | ENTERAL AEROBIZATION THERAPY |
| US20230210848A1 (en) * | 2020-04-30 | 2023-07-06 | Fujifilm Toyama Chemical Co., Ltd. | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157720A (ja) * | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| IL124788A (en) * | 1998-06-07 | 1999-04-11 | Ben Hador David | Boomerang launcher |
| US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
| US20060198901A9 (en) * | 1999-10-26 | 2006-09-07 | Holloway William D Jr | Drugs, bio-affecting and body treating compositions |
| EP1237578A4 (en) * | 1999-10-26 | 2004-10-27 | Bio Hydration Res Lab Inc | MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| JP4064671B2 (ja) * | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| US20030199089A1 (en) * | 2001-06-05 | 2003-10-23 | Surber Mark W. | Membrane to membrane delivery |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
| JP4144669B2 (ja) * | 2004-03-05 | 2008-09-03 | 独立行政法人産業技術総合研究所 | ナノバブルの製造方法 |
| US20060073212A1 (en) * | 2004-04-22 | 2006-04-06 | Palmer Craig R | Method of treating respiratory disorders and airway inflammation |
| CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| US20060273016A1 (en) * | 2005-06-03 | 2006-12-07 | BAGLEY David | Method for preparing water with a stable negative oxidation reduction potential (ORP) |
| WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| JP2011050844A (ja) * | 2009-09-01 | 2011-03-17 | Kurita Water Ind Ltd | 電気浸透脱水方法及び装置 |
-
2008
- 2008-10-23 MX MX2010004549A patent/MX2010004549A/es active IP Right Grant
- 2008-10-23 CA CA2703648A patent/CA2703648A1/en not_active Abandoned
- 2008-10-23 AU AU2008316708A patent/AU2008316708A1/en not_active Abandoned
- 2008-10-23 JP JP2010531258A patent/JP5586470B2/ja not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/081029 patent/WO2009055620A1/en not_active Ceased
- 2008-10-23 CN CN200880122810.7A patent/CN101909869B/zh not_active Expired - Fee Related
- 2008-10-23 EP EP08842668A patent/EP2207669A4/en not_active Withdrawn
- 2008-10-27 JP JP2010531321A patent/JP5647897B2/ja not_active Expired - Fee Related
- 2008-10-27 CN CN200880122809.4A patent/CN101909649B/zh not_active Expired - Fee Related
- 2008-10-27 EP EP08841984.1A patent/EP2214712B1/en not_active Not-in-force
- 2008-10-27 AU AU2008316556A patent/AU2008316556B2/en not_active Ceased
- 2008-10-27 CA CA2703714A patent/CA2703714A1/en not_active Abandoned
- 2008-10-27 CN CN201310717654.1A patent/CN103721258B/zh not_active Expired - Fee Related
-
2010
- 2010-04-25 IL IL205321A patent/IL205321A0/en unknown
- 2010-04-25 IL IL205320A patent/IL205320A/en active IP Right Grant
-
2014
- 2014-11-10 JP JP2014228037A patent/JP5750540B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500838A5 (https=) | ||
| Wang et al. | Controlling Streptococcus mutans and Staphylococcus aureus biofilms with direct current and chlorhexidine | |
| Koo et al. | Targeting microbial biofilms: current and prospective therapeutic strategies | |
| Gupta et al. | Biofilm, pathogenesis and prevention—a journey to break the wall: a review | |
| Ward et al. | Topical agents in burn and wound care | |
| JP2011500844A5 (https=) | ||
| BRPI0416063A (pt) | composição de administração de medicamento por via transdérmica, método de produzir a composição de administração de medicamento por via transdérmica e método de controle de fluxo de um medicmanto de uma composição de administração de medicamento dérmica | |
| GEAP202316271A (en) | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator | |
| DE69935155D1 (de) | Gesteuertes freisetzungssystem zur abgabe von therapeutika in den innenohrkanal | |
| AU4923500A (en) | Device and method for increasing the transdermal permeation of medicaments | |
| PT1492517E (pt) | Sistema terapeutico transdermico termofundivel para administracao de rotigotina | |
| US11541105B2 (en) | Compositions and methods for disrupting biofilm formation and maintenance | |
| CY1118991T1 (el) | Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων | |
| CY1109954T1 (el) | Διαδερμικο θεραπευτικο συστημα (tts) με τη δραστικη ουσια φεντανυλη | |
| FR2734729B1 (fr) | Dispositif pour l'administration transdermique, par transfert electrique, de fentanyl ou de sufentanil | |
| BRPI0512146A (pt) | métodos para o tratamento de uma infecção endobrÈnquica em um paciente, e de um paciente com fibrose cìstica, sofrendo de uma infecção endobrÈnquica | |
| ATE361073T1 (de) | Neue formulierungen zur transdermalen verabreichung von pergolid | |
| TR200002786T2 (tr) | Meloksikam için yeni galenik bir formülasyon. | |
| EP1651676A4 (en) | GLUCAN FOR IMPROVING THERAPY | |
| MXPA05008649A (es) | Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios. | |
| KR960700756A (ko) | 신규한 세포 활성 조절제(novel agent for controlling gell activity) | |
| GB2317569A (en) | Device for transdermal electrotransport delivery of fentanyl and sufentanil | |
| Ochoa-Aguilar et al. | Ceftriaxone and clavulanic acid induce antiallodynia and anti-inflammatory effects in rats using the carrageenan model | |
| BR0316275A (pt) | Administração dérmica de um inibidor seletivo de ciclooxigenase-2, solúvel em água, por exemplo, parecoxibe e valdecoxibe | |
| Jayakumar et al. | Efficacy of Lysostaphin functionalized silicon catheter for the prevention of Staphylococcus aureus biofilm |